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820Objective: To examine the role of radical segmentectomy, defined as a segmentectomy with extensive hilar/
mediastinal lymph node dissection and a sufficient surgical margin, for local control in cT1 N0 M0/pN1-2
non–small cell lung cancer (NSCLC), we examined the following: (1) whether metastases were observed in
specimens additionally resected by completion lobectomy undertaken after segmentectomy because of pN1-2
disease and (2) prognostic outcome in patients whose operations were completed with segmentectomy
regardless of pN1-2.
Methods: Of 275 patients with cT1 N0 M0 NSCLC who were scheduled to undergo radical segmentectomy,
15 (6%) had a diagnosis of pN1 or N2 disease. Of these patients, 10 were additionally treated with completion
lobectomy, whereas the operations of the remaining 5 were completed with segmentectomy.
Results: None of the 10 patients who underwent completion lobectomy showed residual metastases in the spec-
imens additionally resected by completion lobectomy. Two of the 5 patients whose operations were completed
with segmentectomy, regardless of N1 or N2 disease, had tumor recurrence, but their first recurrence was not
local.
Conclusions: Radical segmentectomy, with extensive hilar/mediastinal lymph node dissection and a sufficient
surgical margin, may play a role in local control in patients with cT1 N0 M0/pN1–2 NSCLC. (J Thorac Cardi-
ovasc Surg 2012;143:820-4)In 1995, the Lung Cancer Study Group reported results of
a prospective randomized controlled trial that assessed lim-
ited resection versus lobectomy for clinical T1 N0 M0 non–
small cell lung cancer (NSCLC), concluding that the former
was inferior to the latter because of greater local recurrence
and poorer survival.1 Local recurrences after segmentec-
tomy are known to be caused by the following factors: (1)
insufficient surgical margin, (2) missed intrapulmonary me-
tastases within the same lobe, and (3) missed lymph node
metastases at the hilum and/or mediastinum. To avoid over-
looking lymph node metastases, we submitted dissected
lymph nodes for intraoperative examination to confirm the
intraoperative N staging to be N0. However, we are usually
worried about local recurrence at regional lymph nodes
after segmentectomy, even if the intraoperative N staging
was N0, because of the following: (1) intraoperative frozene Department of General Thoracic Surgery,a School of Medicine, Keio
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The Journal of Thoracic and Cardiovascular Surgsection diagnosis cannot always recognize metastases in all
of the lymph nodes and (2) the dissection of intrapulmonary
lymph nodes remaining within the preserved segment is
impossible.
Since April 2005, we have been conducting radical seg-
mentectomy, defined as a segmentectomy with hilar/medi-
astinal lymph node dissection and taking a sufficient
surgical margin in patients with cT1 N0 M0 NSCLC.2 For
accurate intraoperative N staging, we usually identify senti-
nel nodes (SNs) after dissection of hilar/mediastinal lymph
nodes, including segmental nodes of the preserved seg-
ments.3 When intraoperative frozen sections of the SNs
show metastasis, we usually perform completion lobec-
tomy. In the present study, to examine the role of segmen-
tectomy with this systematic lymph node dissection as
a local control in patients with cT1 N0 M0 NSCLC in
whom pN1 or N2 disease was finally diagnosed, we exam-
ined whether lymph node metastasis remained within the
specimens additionally resected by completion lobectomy.
We also examined the prognostic outcome of patients
with cT1 N0 M0 whose operations were completed with
segmentectomy regardless of pN1 or N2 stage.
PATIENTS AND METHODS
Eligibility
The study protocol for segmentectomy using radioisotopes for SN iden-
tification in patients with cT1 N0 M0 NSCLC was approved by the ethicsery c April 2012
TABLE 1. Pulmonary segment nomenclature
Lobe
Right upper lobe
S1 Apical
S2 Dorsal
S3 Ventral
Left upper lobe
S1þ2 Apicodorsal
S3 Ventral
S4 Lingular superior
S5 Lingular inferior
Lower lobe
S6 Superior
S7 Mediobasal
S8 Ventrobasal
S9 Laterobasal
S10 Dorsobasal
TABLE 2. Lymph node nomenclature
N2 node N1 node
Superior mediastinal Hilar
#2 Upper paratracheal #10 Hilar
#3 Prevascular and retrotracheal #11 Interlobar
#4 Lower paratracheal #12 Lobar
#5 Subaortic Intrapulmonary
#6 Para-aortic #13 Segmental
#14 Subsegmental
Inferior mediastinal
#7 Subcarinal
#8 Paraesophageal
#9 Pulmonary ligament
Abbreviations and Acronyms
NSCLC ¼ non–small cell lung cancer
SN ¼ sentinel node
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segmentectomy in the study were as follows: (1) peripheral type cT1 N0
M0 NSCLC; (2) exclusion of tumors of the right middle lobe; (3) no evi-
dence of metastasis on intraoperative frozen sections of lymph nodes; (4)
surgical margin more than 2 cm or longer than tumor size; (5) normal serum
level of carcinoembryonic antigen; and (6) segmentectomy requested by
patients. Clinical staging was performed by body computed tomographic
scanning, brain magnetic resonance imaging, and fluorodeoxyglucose pos-
itron emission tomography in all patients. Lymph node biopsy via endo-
bronchial ultrasonography was conducted for swelling lymph nodes,
whereas mediastinoscopy was not undertaken. All patients provided in-
formed consent after fully discussing the risks and benefits of segmentec-
tomy with their surgeons.
Patients
From April 2005 to March 2009, 247 patients with cT1 N0 M0 NSCLC
underwent surgical treatment at Kumamoto University Hospital. From
April 2009 to March 2011, 130 patients with cT1 N0 M0 underwent surgi-
cal treatment at Keio University Hospital. Segmentectomy was planned in
275 (73%) of the total 377 patients, lobectomy in 59 (16%), and wedge
resection in 43 (11%). A corresponding author (H.N.) participated in all
of these segmentectomies. The reasons for conducting lobectomy in the
59 patients were tumors existed in the right middle lobe in 27 patients, cen-
trally located tumors in 10, multiple lesions in the same lobe in 9, high car-
cinoembryonic antigen level in 7, patient’s request for lobectomy in 5, and
severe emphysematous change of the tumor-existing lobe in the remaining
1. Of the 275 patients who were scheduled for segmentectomy, 205 (75%)
underwent SN identification using 99mtechnetium-tin colloid or 99mtechne-
tium-phytate to target lymph nodes submitted for intraoperative frozen sec-
tion diagnosis, as reported before,4-7 whereas the remaining 70 (25%) did
not. The nomenclature used for pulmonary segments is shown in Table 1.
Operative Procedures and Lymph Node Evaluation
Although the SNs were identified in the present study, the purpose of
this study was to target lymph nodes submitted for intraoperative frozen
section but not to reduce lymph node dissection. Under thoracotomy,
segmentectomy with lymph node dissection was performed as reported
previously.3 After resection of the affected segment, lymph node stations
10 to 13, including station 13 of preserved segments, were dissected.
Lymph nodes at both the superior and inferior mediastinumwere dissected,
regardless of tumor location. The identified SNs were submitted for intra-
operative frozen section diagnosis. They were serially cut to about 3 mm in
thickness followed by hematoxylin and eosin staining to detect even a small
metastasis. If the intraoperative frozen sections of SNs showed no metasta-
sis, the operation was completed with segmentectomy. If the frozen sec-
tions of SNs showed metastasis, completion lobectomy was performed.
SNs were further examined immunohistochemically after surgery by using
anticytokeratin AE1/AE3 antibody (Dako Corporation, Carpinteria, Calif)
to identify possible microscopic metastases. For patients in whom SN
identification was not conducted, at least the No. 12, No. 13, and lobe-
specific mediastinal nodes were submitted for frozen sections. Lymph
node nomenclature and tumor staging were based on the 2009 Staging
Manual in Thoracic Oncology of the International Association for the
Study of Lung Cancer (Table 2).8 During the operation, the surgical margin
was confirmed to be sufficiently longer than 2 cm or themaximum diameter
of the tumor.The Journal of Thoracic and CaPathologic Examination of Specimens Resected by
Completion Lobectomy
The specimens additionally resected by completion lobectomy, that is,
the resection of the preserved lobe after segmentectomy, were pathologi-
cally examined. The lymph nodes within the additionally resected speci-
mens were also examined by immunohistochemical staining using
anticytokeratin antibody.
Postoperative Follow-up
All patients were followed up every 3 to 6 months after surgery until 5
years after surgery and yearly thereafter. The follow-up period ranged from
6 to 73 months, both of which average andmedian periods were 41 months.
Patients with pN1 or N2 were usually treated by chemotherapy after sur-
gery with platinum doublet.RESULTS
Lymph node metastases were found in 15 (6%) of the
275 patients who were scheduled for segmentectomy. The
surgical margin was free of tumor in all of the 15 patients.
Of the 15 patients with lymph node metastases, 10 under-
went completion lobectomy after segmentectomy (Table
3). All of these 10 patients showed metastases in SNs.
Patients 5, 6, and 8 underwent completion lobectomyrdiovascular Surgery c Volume 143, Number 4 821
TABLE 3. Patients underwent completion lobectomy after segmentectomy because of N1 or N2 disease
No. (age/sex) cTNM
Tumor
LN metastasis Segmentectomy
Completion
lobectomy pTNM
First
recurrence site OutcomeHistology Size (cm)
1 (50/F) T1b N0 M0 Ad 2.7 #5, 6, 10, 12 lt. S1-3 LUL T1a N2 M0 Brain 38 mo, dead
2 (72/M) T1a N0 M0 Ad 2.0 #11 rt. S6 RLL T1a N1 M0 Pleura 24 mo, dead
3 (54/F) T1b N0 M0 Ad 2.4 #7, 12 lt. S9þ10 LLL T2 N2 M0 — 67 mo, alive
4 (73/M) T1a N0 M0 Sq 2.0 #5 lt. S1þ2 LUL T1a N2 M0 — 39 mo, alive
5 (35/F) T1b N0 M0 Ad 2.2 #12 lt. S6 LLL T1b N1 M0 — 20 mo, alive
6 (38/F) T1b N0 M0 Ad 2.3 #12 lt. S1-3 LUL T1b N1 M0 — 19 mo, alive
7 (58/M) T1a N0 M0 Ad 1.3 #4 rt. S1 RUL T1a N2 M0 — 10 mo, alive
8 (47/F) T1a N0 M0 Ad 1.6 #13 lt. S9þ10 LLL T1a N1 M0 — 9 mo, alive
9 (63/M) T1b N0 M0 Ad 2.1 #12 rt. S8 RLL T3 N2 M0 — 7 mo, alive
10 (51/M) T1a N0 M0 Ad 2.0 #4 rt. S9 RLL T1a N2 M0 — 6 mo, alive
LN, Lymph node; Ad, adenocarcinoma; Sq, squamous cell carcinoma; rt., right; lt., left; LUL, left upper lobe; RLL, right lower lobe; LLL, left lower lobe; RUL, right upper lobe.
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chemical staining on deep cut section of the SN after sur-
gery showed micrometastasis, whereas intraoperative
frozen sections showed no metastasis by hematoxylin and
eosin staining. In none of these 10 patients did specimens
additionally resected by completion lobectomy show resid-
ual tumors in the lungs or lymph nodes, even with immuno-
histochemical staining. Whereas patients 1 and 2 died of the
disease, the remaining 8 patients are alive without disease
through July 2011.
The remaining 5 patients had their operations completed
by segmentectomy regardless of pN1 or N2 disease (Table
4), for the following reasons: (1) old age in patients 11
and 12; (2) patient’s request in patient 13; (3) central-type
squamous cell carcinoma at the segmental bronchus in pa-
tient 14 with poor pulmonary function, which was treated
with sleeve segmentectomy; and (4) double lung cancers
in patient 15, both of which were resected by segmentec-
tomy. Although patients 11 and 12 died of the disease, their
first recurrence sites were distant organs. The other 3 pa-
tients are alivewithout disease 6, 9, 28 months after surgery,
respectively.
Skip metastases to the mediastinal lymph nodes were
found in 4 (27%) of the 15 patients: patients 4, 7, 10, and
12. Of these, the patient with adenocarcinoma in the right
lower lobe (patient 10) had single metastasis at the #4R,
which was not a lobe-specific mediastinal node.TABLE 4. Patients whose operations were completed with segmentectomy
No. (age/sex)
Tumor
Size (cm) LN metastasis ScTNM Histology
11 (80/M) T1b N0 M0 Ad 2.5 #5, 12, 13
12 (81/M) T1a N0 M0 Ad 1.0 #4
13 (68/F) T1a N0 M0 Ad 1.2 #4, 12, 13
14 (75/M) T1a N0 M0 Sq 1.5 #13
15 (62/M) T1b N0 M0 Ad* 2.3 #13
T1a N0 M0 Ad* 1.5 —
LN, Lymph node; Ad, adenocarcinoma; Sq, squamous cell carcinoma; lt., left. *Double lu
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The present results highlight the following 3 points: (1)
the specimens additionally resected by completion lobec-
tomy did not show any residual metastases even with immu-
nohistochemical staining in the 10 patients with pN1 or N2
disease; (2) although 2 of the 5 patients who had their oper-
ations completed by segmentectomy regardless of pN1 or
N2 disease died of the disease, their first recurrence sites
were not local; and (3) whereas the follow-up period is still
not sufficient, the remaining 3 of the 5 patients who had
their operations completed by segmentectomy regardless
of N1 or N2 have been alive without recurrences. These re-
sults indicate that segmentectomy may play a role in local
control in patients with cT1 N0 M0/pN1-2 NSCLC if com-
bined with systematic lymph node dissection of the hilum
and mediastinum and sufficient surgical margin.
Skip metastasis to the mediastinal lymph nodes has been
reported to occur in 20% to 40% of patients with NSCLC,9
which may be caused by some lymphatic flow going di-
rectly to the mediastinum rather than to the hilum. Four
(27%) of the present 15 patients also showed skip metasta-
sis to the mediastinal lymph nodes. Therefore, mediastinal
lymph node dissection is necessary during segmentectomy
even in patients with cT1 N0 M0 NSCLC. Although the
American College of Surgeons Oncology Group Z0030 ran-
domized controlled trial between mediastinal lymph node
dissection versus sampling showed no difference,10 weregardless of N1 or N2 disease
egmentectomy pTNM First recurrence Outcome
lt. S1-3 T1b N2 M0 Intestineþmediastinum 20 mo, dead
lt. S4þ5 T1a N2 M0 Liver 18 mo, dead
lt. S8 T1a N2 M0 — 27 mo, alive
lt. S1þ2 T1a N1 M0 — 9 mo, alive
lt. S1-3 T1b N1 M0 — 6 mo, alive
lt. S6 T2a N0 M0
ng cancers.
ery c April 2012
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verify whether the segmentectomy itself was a radical
procedure for cT1 N0 M0 NSCLC. In the future, segmen-
tectomy with lymph node sampling should be further eval-
uated as a radical treatment or not.
It has been reported that metastasis of mediastinal lymph
nodes is mostly lobe-specific, that is, upper mediastinal
lymph nodes in tumors of the upper lobe and lower medias-
tinal lymph nodes in those of the lower lobe.9,11 However, 1
of the present patients, who had primary tumors in the right
lower lobe, showed metastasis only at the upper mediastinal
node, that is, #4R, which was not lobe-specific. We6 previ-
ously reported that the SNs of NSCLCs in the right lower
lobe were found in #4R at a rate of 36%. We therefore be-
lieve that #4R should be the target of lymph node sampling
for cT1 N0 M0 NSCLCs of the right lower lobe, not only
during segmentectomy but also during lobectomy.
The final indication for segmentectomy in most of the
present patients (75%) was determined by intraoperative
frozen section diagnosis of SNs identified by the radioiso-
tope method. However, we consider that SN identification
is not always necessary for intraoperative N staging during
segmentectomy. In its place, if SN identification is not used
during segmentectomy, all of the dissected lymph nodes
should be submitted theoretically for frozen section diagno-
sis, because the frequency of lymph node metastasis in cT1
N0 M0 NSCLC is reported to be about 10% as reported in
the recent Japanese Lung Cancer Registry Study.12 How-
ever, intraoperative frozen section diagnosis of all dissected
lymph nodes is not feasible. Therefore, when not using SN
identification, we usually target lymph nodes submitted for
frozen section diagnosis during segmentectomy as follows:
(1) hilar lymph nodes 12 and 13 are submitted for frozen
section rather than nodes 10 or 11, because our previous
study showed that SN rates for nodes 12 and 13 were
39% and 57%, respectively, whereas those for nodes 10
and 11 were only 10% and 16%, respectively5; (2) in
mediastinal lymph nodes, the largest lymph node in each
station is submitted for frozen section, because they had
almost 90% of the rate of having metastasis in N2 disease
according to our previous report13; and (3) although lobe-
specific mediastinal nodes should be targeted, the #4R is
also submitted for intraoperative frozen section in NSCLC
of the right lower lobe, on the basis of our previous
findings.6
Whereas several reports have shown that segmentectomy
provides a similar prognosis as lobectomy for T1 N0 M0
NSCLC,14-16 our study presents the possibility of radical
segmentectomy as a local control even for cT1 N0 M0/
pN1-2 NSCLC. The radical segmentectomy described in
the present study should be distinguished from a simple seg-
mentectomy on the basis of the extent of lymph node dissec-
tion. It seems similar to the ‘‘radical lobectomy’’ proposed
by Cahan17 in 1960, when pneumonectomy was a standardThe Journal of Thoracic and Caprocedure. Cahan defined a radical lobectomy as an opera-
tion in which 1 or 2 lobes were excised in a block dissection
with their regional hilar and mediastinal lymph nodes. After
his proposal, lobectomy with mediastinal lymph node
dissection replaced pneumonectomy even for N1 or N2
disease, and this technique has been established as a stan-
dard procedure for NSCLC to date. However, even after
radical lobectomy, several studies have reported the
development of local recurrences, at a rate of 6%.1,18 We
therefore consider that that local recurrence after radical
segmentectomy may be acceptable at a rate of up to 6%;
in contrast to this hypothesis, the present study showed
neither local recurrence after segmentectomy nor tumors
within the specimens additionally resected by completion
lobectomy.
Even by using extensive lymph node dissection and tak-
ing a sufficient surgical margin during segmentectomy, the
procedure may miss pulmonary metastases within the same
lobe. However, the recently developed high-resolution com-
puted tomography can identify pulmonary lesions even just
0.3 cm in size, which can lead to a correct indication for
segmentectomy.
Here, we present pathologic results of specimens addi-
tionally resected by completion lobectomy in patients
with cT1 N0 M0/pN1-2 NSCLC and the prognostic out-
come of patients whose operations were completed by seg-
mentectomy regardless of pN1 or N2 disease. On the basis
of our promising findings, we could not find any merit of
completion lobectomy after radical segmentectomy. We be-
lieve that radical segmentectomy, with extensive hilar/me-
diastinal lymph node dissection and taking a sufficient
surgical margin, may play as much of a role in local control
as lobectomy in patients with cT1 N0 M0/pN1-2 NSCLC.References
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